Research reference only — not a catalog item
Vesugen
Research context
Published mouse work administered the tripeptide Vesugen (Lys-Glu-Asp, KED) intraperitoneally to 5xFAD mice and recorded dendritic-spine morphology.
What has been studied
- Mouse model
- In vitro model
Khavinson et al. (2021) administered the tripeptide Vesugen (Lys-Glu-Asp) intraperitoneally to 5xFAD mice and recorded dendritic-spine morphology. The paper also describes an in vitro amyloid synaptotoxicity model. A 2025 correction was issued for this article.
These labels restate the setting of the cited paper. They are not new findings and do not describe a catalog material.
Research model areas
- 5xFAD mouse dendritic-spine counts
- In vitro amyloid synaptotoxicity model
Selected published literature
- Khavinson et al. (2021), Pharmaceuticals · PMID 34071923
- Khavinson et al. (2025), Pharmaceuticals correction · PMID 39861198
What remains uncertain
Limitations
A 2025 correction was issued for this paper (PMID 39861198). The mouse experiment does not establish a human neurological outcome, and this note does not describe a vascular use.
Model areas in the Body Explorer: Neural signaling models.